Jul 26, 2017 11:30 am UTC| Business
PILLAR study demonstrated a 78 percent decrease in opioid consumption and significantly better pain control with infiltration of EXPAREL plus bupivacaine versus bupivacaine alone Ten percent of patients in the EXPAREL...
Alliqua BioMedical, Inc. to Announce Second Quarter of Fiscal Year 2017 Results on August 10th
Jul 26, 2017 11:30 am UTC| Business
YARDLEY, Pa., July 26, 2017 -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a regenerative medicine company committed to restoring tissue and rebuilding lives, today announced plans to release...
Nasdaq Announces Quarterly Dividend of $0.38 Per Share
Jul 26, 2017 11:20 am UTC| Business
NEW YORK, July 26, 2017 -- The Board of Directors of Nasdaq, Inc (Nasdaq:NDAQ) has declared a regular quarterly dividend of $0.38 per share on the company's outstanding common stock. The dividend is payable on...
Nasdaq Reports Second Quarter 2017 Results; Achieves Record Quarterly Net Revenues
Jul 26, 2017 11:20 am UTC| Business
Net revenues1 were a record $602 million in the second quarter of 2017, an increase of 8% compared to the second quarter of 2016. Subscription and recurring revenues2 increased 5% compared to prior year period and...
Nasdaq Elects New Board Member
Jul 26, 2017 11:20 am UTC| Business
NEW YORK, July 26, 2017 -- Nasdaq (Nasdaq:NDAQ) today announced the addition of John D. Rainey to the Nasdaq Board of Directors following his election by the board on July 25, 2017. John is Executive Vice President...
SyncHR Successfully Closes $16 Million Round of Funding Led by NEA
Jul 26, 2017 11:14 am UTC| Business
DENVER, July 26, 2017 -- SyncHR, a leader in Human Capital Management (HCM) cloud-based software, announced today that the company recently secured $16 million in additional funding. The Company’s existing investors...
Intercept to Report Second Quarter 2017 Financial Results on July 31
Jul 26, 2017 11:05 am UTC| Business
NEW YORK, July 26, 2017 -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases,...